

**THE NEED:** Oncologists today have a wide selection of therapies to offer their patients, but few tools to help guide their choices, especially once treatment is underway. Patients routinely receive multiple cycles of treatment before understanding whether their disease is responding. Scans are imprecise and lagging indicators of response, biopsies are invasive and expensive, and many of the genetic testing options today are unproven.

### PRODUCTS:

- **HERTEST™** is a sensitive, accurate, and easily administered serum test that measures circulating HER2. Changes in HER2 have been proven to indicate tumor response in breast, gastric, bladder, and other cancers
- **CHECKMARK™** accurately measures serum PD-L1, a cancer biomarker that is overexpressed in many lung, colon and other cancers.
- **Martell products**, including a growing portfolio of other biomarker tests, will provide real-time feedback to oncologists and their patients


### MARKET OVERVIEW – BREAST CANCER

- 300K patients are diagnosed each year in the US, all need testing and 40% would benefit from repeated testing throughout treatment
- 3 million women are breast cancer survivors at risk for recurrent disease which can be HER2 positive, regardless of the initial breast cancer type

### DEVELOPMENT AND COMMERCIALIZATION

- Validated LDT available now
- Clinical studies underway to drive adoption
- Expected Launch January 2022
- Average Selling Price: \$300
- Expected Gross Margin >80%

**MANAGEMENT** - Full time staff of four, with a team of 12 part time advisers and consultants committed to the concept of an effective, efficient liquid biopsy for breast cancer patients



A normal cell may express 40,000 HER2 proteins, while a breast cancer cell may express 500,000.

### HIGHLIGHTS

- **Well-known assay using a validated approach to Breast Cancer management**
- **Clearly identified initial market, with multiple additional areas for growth**
- **Strong Leadership and Board with 100+ years of collective, broad expertise**
- **Innovative platform with multiple potential liquid biopsy products**

**For more information contact:**

Michelle Edwards, CEO 415-713-8397 medwards@martelldiagnostic.com